Carbamazepine (Psychiatric Use)
Brand names: Tegretol, Tegretol Retard (modified-release)
Carbamazepine is used in psychiatry as a mood stabiliser, principally for the prophylaxis of bipolar affective disorder in patients unresponsive to lithium, and in acute mania.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It stabilises hyperexcitable neuronal membranes mainly by blocking voltage-gated sodium channels, reducing repetitive neuronal firing and pathological neurotransmission.
Prescribing in practice
- It is a potent inducer of hepatic enzymes and therefore reduces the effectiveness of many co-prescribed drugs, including hormonal contraceptives, so interaction checks are essential.
- Warn patients about signs of blood, liver and skin disorders (including potentially life-threatening rashes such as Stevens-Johnson syndrome) and the increased serious-cutaneous-reaction risk associated with the HLA-B*1502 allele in relevant ancestries.
- It is teratogenic and should be avoided in pregnancy and in women of childbearing potential not using effective contraception unless there is no safer alternative.
Monitoring
Monitor full blood count, liver function and, where indicated, plasma carbamazepine concentration, alongside review of mood and emergent rashes.
Counselling the patient
- Seek urgent medical advice if you develop a fever, mouth ulcers, bruising, a rash or yellowing of the skin.
- This drug can stop hormonal contraception working, so discuss reliable contraception.
- Do not stop suddenly without medical advice.
Evidence & guidelines
Carbamazepine is recognised in NICE guidance as a mood-stabilising option in bipolar disorder; MHRA advice highlights teratogenicity and serious cutaneous reactions.
Reference: NICE CG185 (Bipolar Disorder); MHRA HLA-B*1502 Safety Update; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Modified Mallampati Classification · Airway Assessment
- Modified Early Warning Score (MEWS) · Early Warning
- Modified Shock Index (MSI) · Haemodynamic Assessment
- Modified Sgarbossa's Criteria (Smith Modification) for MI in LBBB · ECG Interpretation
- MAGGIC Heart Failure Risk Score · Heart Failure
- Long QT Syndrome (Schwartz Score) · Channelopathy / Sudden Cardiac Death
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185